Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.720 -2.550 (-59.72%)
Streaming Delayed Price Updated: 3:41 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,693,379
Open 1.460
Bid (Size) 1.720 (12)
Ask (Size) 1.730 (126)
Prev. Close 4.270
Today's Range 1.320 - 2.280
52wk Range 3.072 - 41.76
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Is Azitra (AZTR) Stock Up 315% Today?
Azitra stock is up on Tuesday alongside heavy trading of AZTR shares after it provided investors with an update on new patents. 
Via InvestorPlace

Performance

YTD
-81.04%
-81.04%
1 Month
-54.61%
-54.61%
3 Month
-84.06%
-84.06%
6 Month
-72.06%
-72.06%
1 Year
-95.52%
-95.52%

More News

Read More
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Jaguar Health Stock Is Crashing
Via Benzinga
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Via ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Via ACCESSWIRE
Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading
Via InvestorPlace
Topics ETFs
Why Is Serve Robotics (SERV) Stock Down Today?
Via InvestorPlace
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Via InvestorPlace
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Via ACCESSWIRE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Via ACCESSWIRE
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Via ACCESSWIRE
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
Via ACCESSWIRE
What's Going On With Jaguar Health Stock?
Via Benzinga
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Via ACCESSWIRE
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
Via Benzinga
Topics Stocks
Exposures US Equities
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.